Trial · NCT01465659
Participant flow64
How many started, completed or left each group, period by period.
1 to 20 of 64
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Completed 1 Cycle of Treatment | STARTED | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | 7 | |
| Completed 1 Cycle of Treatment | STARTED | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | 5 | |
| Completed 1 Cycle of Treatment | STARTED | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | 6 | |
| Completed 1 Cycle of Treatment | STARTED | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | 11 | |
| Completed 1 Cycle of Treatment | Completed 1 Cycle of Treatment | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | 7 | |
| Completed 1 Cycle of Treatment | Completed 1 Cycle of Treatment | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | 4 | |
| Completed 1 Cycle of Treatment | Completed 1 Cycle of Treatment | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | 6 | |
| Completed 1 Cycle of Treatment | Completed 1 Cycle of Treatment | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | 11 | |
| Completed 1 Cycle of Treatment | COMPLETED | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | 7 | |
| Completed 1 Cycle of Treatment | COMPLETED | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | 4 | |
| Completed 1 Cycle of Treatment | COMPLETED | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | 6 | |
| Completed 1 Cycle of Treatment | COMPLETED | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | 10 | |
| Completed 1 Cycle of Treatment | NOT COMPLETED | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | 0 | |
| Completed 1 Cycle of Treatment | NOT COMPLETED | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | 1 | |
| Completed 1 Cycle of Treatment | NOT COMPLETED | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | 0 | |
| Completed 1 Cycle of Treatment | NOT COMPLETED | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | 1 | |
| Completed 2 Cycles/Reached 1st Response | STARTED | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | 7 | |
| Completed 2 Cycles/Reached 1st Response | STARTED | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | 4 | |
| Completed 2 Cycles/Reached 1st Response | STARTED | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | 6 | |
| Completed 2 Cycles/Reached 1st Response | STARTED | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01465659/flow